Skip to main
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure is a leader in surgical treatments for cardiac conditions and pain management, with a strong focus on innovation and growth. Their diverse product line and strong sales force position them well for continued double-digit growth, and we anticipate improved profitability in the coming years. Despite trading at a lower EV/sales multiple than its peers, we believe AtriCure's multiple shots on goal in 2026 and beyond justify a higher valuation, leading us to reiterate our market outperform rating with a price target of $52.

Bears say

AtriCure is a company that operates in the medical industry and specializes in surgical treatments for various heart conditions. Despite a strong balance sheet and expected growth in revenue and earnings, we believe the launch of MDT's Penditure LAAC device will result in a significant slowdown in AtriCure's Appendage Management growth, which will negatively impact its profitability and cash flow. As such, we have a negative outlook on the company's stock.

AtriCure (ATRC) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Strong Buy based on their latest research and market trends.

According to 6 analysts, AtriCure (ATRC) has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.